Bioton S.A. is a Polish biotechnology company specializing in the development, manufacturing, and distribution of recombinant human insulin and generic pharmaceuticals. Headquartered in Macierzysz near Warsaw, the company is among the first four organizations globally capable of producing recombinant human insulin, a critical treatment for diabetes management. Beyond insulin, Bioton manufactures a range of generic drugs, including cephalosporin antibiotics, aminoglycosides, and macrolides. The company operates a modern manufacturing facility featuring state-of-the-art technological solutions for drug synthesis and production. Bioton serves global markets with a strategic focus on key regions including Poland, Russia, Ukraine, China, India, and other Asia Pacific countries. The company pursues research and development initiatives to expand its product portfolio and pursues strategic partnerships with leading pharmaceutical organizations. Through its commitment to biotechnology innovation, Bioton addresses the growing worldwide demand for insulin therapies and other clinically important medicines, positioning itself as a significant player in the international healthcare and pharmaceutical landscape.